Amid a month of skyrocketing stock prices and unprecedented social media buzz, Hims & Hers Health is expanding its territory into at-home blood testing and diagnostics.

Shares of Hims & Hers Health Inc (HIMS 20.27%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p.m.

Hims & Hers Health stock has surged 212% since my previous “buy” rating. Despite strong revenue and earnings growth expectations, I recommend holding off at the moment. Hims & Hers has consistently...

Shares of Hims & Hers (HIMS -0.96%) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the comp...

Hims & Hers Health's NYSE: HIMS share price has surged recently, climbing above $60 and creating new 52-week and all-time record highs for the company. This significant increase in Hims & Hers Heal...

Shares of direct-to-consumer telehealth platform Hims & Hers Health (HIMS 2.18%) have become a runaway freight train. The stock has returned nearly 20-fold returns from its 2022 lows, including a b...

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $60.30, signifying a +1.88% move from its prior day's close.

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...

Hims & Hers (HIMS 1.82%) launched a Super Bowl ad this week, and everyone from pharmaceutical companies to pharmacists tried to block it. Travis Hoium explains why that's a great sign that the comp...

Hims & Hers has shown significant growth, with a 350% stock gain in 2024, driven by subscriber and revenue increases, and positive free cash flow. The company boasts a strong balance sheet with $25...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NVO -2.90%), famously the company behind Wegovy, a...

CNBC's Brandon Gomez joins 'Squawk on the Street' to break down the controversy around Hims & Hers Super Bowl ads.

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has soared by almost 1,500% from its lowest level in 2023, transforming it ...

Telehealth company Hims & Hers Health is fighting back after the drug industry's main lobbying group called out its first Super Bowl ad as “misleading” and in potential violation of marketing rules.

Stock markets got a bit of a shock on Friday after a University of Michigan survey showed consumers are anticipating inflation to rise in 2025, potentially depressing consumer spending and dissuadi...